Adaptive Biotechnologies (ADPT) Long-Term Investments (2019 - 2026)

Adaptive Biotechnologies has disclosed Long-Term Investments across 7 years of filings, most recently posting $27.5 million for Q2 2026.

• In Q2 2026, Long-Term Investments rose 14.02% year-over-year to $27.5 million; the TTM figure through Jun 2026 stood at $27.5 million (up 14.02% YoY), while the FY2025 annual figure was $13.2 million, down 60.68% from the prior year.
• Long-Term Investments came in at $27.5 million for Q2 2026 at Adaptive Biotechnologies, up from $18.9 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $137.1 million in Q1 2022 to a low of $4.0 million in Q3 2025.
• Average Long-Term Investments over 4 years is $37.1 million, with a median of $24.1 million recorded in 2025.
• The largest YoY upside for Long-Term Investments was 346.79% in 2022 against a maximum downside of 90.94% in 2022.
• Over 4 years, Long-Term Investments stood at $19.7 million in 2022, then surged by 70.88% to $33.7 million in 2024, then tumbled by 60.68% to $13.2 million in 2025, then jumped by 107.65% to $27.5 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $27.5 million in Q2 2026, $18.9 million in Q1 2026, and $13.2 million in Q4 2025.